Biotech Values

[BioSpecialist]

Parkinson disease Positive PIII data ...


Newron Pharma (NRWN.SW) Listed on Swiss Exchange

MarketCap : 99,97 Mio CHF ( 88,26 Mio US$ )
Cash : 62,38 Mio CHF ( 55,07 Mio US$ )
Price : 16,5 CHF

Shares Out : 6,03 Mio

Pipeline
http://www.newron.com/uploads/pipeline_111November3.pdf


Safinamide Significantly Improved Motor Function in Patients with Advanced
Parkinson’s Disease in a Phase III Pivotal Trial
http://www.newron.com/uploads/SAfinamidePIIIresultsNewronENG3Feb.pdf


Homepage
http://www.newron.com/default.asp


By Julia Mengewein 11.03.2009
Of DOW JONES NEWSWIRES


ZURICH -(Dow Jones)- The ongoing late-stage trial for Newron Pharmaceuticals SpA's (NWRN.EB) back-pain drug candidate ralfinamide is going ahead as planned, Chief Financial Officer Stefan Weber told Dow Jones in an interview Wednesday.

"The trial is going according to plan," Weber said.

News from this study will be pivotal for outlicensing ralfinamide, which could be the first treatment for neuropathic lower back pain, analysts say. Newron plans to release full data of the trial early in 2010, but may strike a deal before then.

"Then (early in 2010) at the latest, we will outlicense the drug," Weber said. He added that talks with potential partners are already ongoing, but declined to elaborate further.

Intermediate data so far has shown that the drug is reducing pain for patients and increasing their quality of life and sleep.

Analysts see sales potential of up to $1.5 billion for ralfinamide in its best years, with market entry expected for around 2012.

Newron, based in Milan, Italy, but listed in Switzerland, will need another late-stage trial of ralfinamide for market approval.

"We want to carry out the second study with a partner," Weber said.

Those companies which specialize in pain should be interested in ralfinamide, analysts say. Among the companies proficient in this area are Pfizer Inc. (PFE), GlaxoSmithKline PLC. (GSK) and also AstraZeneca PLC. (AZN.LN).